107 related articles for article (PubMed ID: 15652624)
1. Functional magnetic resonance mapping of intracerebroventricular infusion of a neuroactive peptide in the anaesthetised rat.
Gozzi A; Schwarz AJ; Reese T; Crestan V; Bertani S; Turrini G; Corsi M; Bifone A
J Neurosci Methods; 2005 Mar; 142(1):115-24. PubMed ID: 15652624
[TBL] [Abstract][Full Text] [Related]
2. A multimodality investigation of cerebral hemodynamics and autoregulation in pharmacological MRI.
Gozzi A; Ceolin L; Schwarz A; Reese T; Bertani S; Crestan V; Bifone A
Magn Reson Imaging; 2007 Jul; 25(6):826-33. PubMed ID: 17451905
[TBL] [Abstract][Full Text] [Related]
3. Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats.
Skoubis PD; Hradil V; Chin CL; Luo Y; Fox GB; McGaraughty S
Neuroscience; 2006; 137(2):583-91. PubMed ID: 16289887
[TBL] [Abstract][Full Text] [Related]
4. In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI.
Schwarz AJ; Gozzi A; Reese T; Bifone A
Neuroimage; 2007 Feb; 34(4):1627-36. PubMed ID: 17188903
[TBL] [Abstract][Full Text] [Related]
5. High resolution spatial mapping of nicotine action using pharmacologic magnetic resonance imaging.
Choi JK; Mandeville JB; Chen YI; Kim YR; Jenkins BG
Synapse; 2006 Aug; 60(2):152-7. PubMed ID: 16715493
[TBL] [Abstract][Full Text] [Related]
6. Drug-anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine.
Gozzi A; Schwarz A; Crestan V; Bifone A
Magn Reson Imaging; 2008 Sep; 26(7):999-1006. PubMed ID: 18486387
[TBL] [Abstract][Full Text] [Related]
7. Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain.
Schwarz A; Gozzi A; Reese T; Bertani S; Crestan V; Hagan J; Heidbreder C; Bifone A
Synapse; 2004 Oct; 54(1):1-10. PubMed ID: 15300879
[TBL] [Abstract][Full Text] [Related]
8. Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI.
Chen YI; Choi JK; Jenkins BG
Synapse; 2005 Feb; 55(2):80-8. PubMed ID: 15529335
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological MRI in awake rats predicts selective binding of alpha4beta2 nicotinic receptors.
Chin CL; Pauly JR; Surber BW; Skoubis PD; McGaraughty S; Hradil VP; Luo Y; Cox BF; Fox GB
Synapse; 2008 Mar; 62(3):159-68. PubMed ID: 18081183
[TBL] [Abstract][Full Text] [Related]
10. A study paradigm allowing comparison of multiple high-resolution rCBV-maps for the examination of drug effects.
Rausch M; Gentsch C; Enz A; Baumann D; Rudin M
NMR Biomed; 2005 Jun; 18(4):260-8. PubMed ID: 15759291
[TBL] [Abstract][Full Text] [Related]
11. Differential responses in CBF and CBV to cocaine as measured by fMRI: implications for pharmacological MRI signals derived oxygen metabolism assessment.
Luo F; Schmidt KF; Fox GB; Ferris CF
J Psychiatr Res; 2009 Aug; 43(12):1018-24. PubMed ID: 19135215
[TBL] [Abstract][Full Text] [Related]
12. Effect of Thunbergia laurifolia, a Thai natural product used to treat drug addiction, on cerebral activity detected by functional magnetic resonance imaging in the rat.
Thongsaard W; Marsden CA; Morris P; Prior M; Shah YB
Psychopharmacology (Berl); 2005 Aug; 180(4):752-60. PubMed ID: 16001121
[TBL] [Abstract][Full Text] [Related]
13. Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naïve rat.
Gozzi A; Schwarz A; Reese T; Bertani S; Crestan V; Bifone A
Neuropsychopharmacology; 2006 Aug; 31(8):1690-703. PubMed ID: 16292320
[TBL] [Abstract][Full Text] [Related]
14. Effects of scopolamine challenge on regional cerebral blood volume. A pharmacological model to validate the use of contrast enhanced magnetic resonance imaging to assess cerebral blood volume in a canine model of aging.
Tapp PD; Chu Y; Araujo JA; Chiou JY; Head E; Milgram NW; Su MY
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):399-406. PubMed ID: 15795048
[TBL] [Abstract][Full Text] [Related]
15. Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M; Boczek-Leszczyk E
J Physiol Pharmacol; 2008 Sep; 59(3):553-62. PubMed ID: 18953097
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine produces changes in cortico-basal thalamic loop circuits: assessed by phMRI BOLD contrast.
Easton N; Marshall F; Fone K; Marsden C
Neuropharmacology; 2007 Mar; 52(3):812-26. PubMed ID: 17140608
[TBL] [Abstract][Full Text] [Related]
17. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
18. Mapping the effects of the selective dopamine D2/D3 receptor agonist quinelorane using pharmacological magnetic resonance imaging.
Ireland MD; Lowe AS; Reavill C; James MF; Leslie RA; Williams SC
Neuroscience; 2005; 133(1):315-26. PubMed ID: 15893653
[TBL] [Abstract][Full Text] [Related]
19. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
20. Imaging of hyperalgesia in rats by functional MRI.
Hess A; Sergejeva M; Budinsky L; Zeilhofer HU; Brune K
Eur J Pain; 2007 Jan; 11(1):109-19. PubMed ID: 16517192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
